Aperio Group’s Arbutus Biopharma ABUS Stock Holding History

Aperio Group’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,234	Closed	-$3K	–	2307
2019 Q2	$3K	Buy	+1,234	New	+$3.16K	﹤0.01%	2884

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Aperio Group's ABUS Position: Q3 2019 in Review

Aperio Group sold out of Arbutus Biopharma (ABUS) in Q3 2019, closing a stake of 1,234 shares — an estimated $3K sold.

Aperio Group first reported a position in ABUS in Q2 2019 and held it in 1 quarter. The position peaked at $3K in Q2 2019. 55 funds tracked by Wall St. Rank hold ABUS as of Q3 2019.

Aperio Group reported no remaining Arbutus Biopharma position as of Q3 2019 after selling out during the quarter.
Aperio Group sold 1,234 Arbutus Biopharma shares in Q3 2019, an estimated $3K.
Aperio Group first reported a position in Arbutus Biopharma in Q2 2019 and held it in 1 quarter.
Aperio Group's Arbutus Biopharma position peaked at $3K in Q2 2019.
55 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.